Topics:

Receptagen to Develop 'Growth Blocker' Monoclonal Antibody

Receptagen to Develop 'Growth Blocker' Monoclonal Antibody

SEATTLE--Receptagen Ltd. has begun formal clinical development of its first "growth blocker" drug, based on promising laboratory studies. The agent, a monoclonal antibody that blocks the B12 carrier protein trans-cobalamin II, triggered apoptosis in cancer cells by depleting vitamin B12, an essential enzyme co-factor for cell proliferation, said Receptagen president A. Charles Morgan Jr., PhD.

 
Loading comments...
Please Wait 20 seconds or click here to close